Plain-English translation of NCT05363397 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called , which is designed to work alongside standard emergency stroke treatments. The medication helps prevent blood clots from forming again after doctors open up a blocked artery in the brain. Researchers want to make sure the medication is safe and doesn't cause harmful bleeding when added to existing stroke therapies.
Even after doctors successfully treat a stroke by removing or dissolving a blood clot, the artery can sometimes get blocked again, which can cause more brain damage. This medication is being tested to see if it can prevent that re-blocking and improve recovery in stroke patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll receive the study medication intravenously as part of your emergency stroke treatment — a quick infusion of the first dose over about one minute, followed by a slower infusion over 3 hours. The study uses a careful step-by-step approach, starting with lower doses and increasing only if safety looks good. You'll be monitored closely during and after treatment to check for any side effects or complications.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Australia